The Book explores the role of PARP inhibitors in advancing cancer therapy, focusing on their effectiveness in targeting cancer cells with specific genetic vulnerabilities. It examines how these drugs improve treatment outcomes for various cancers, particularly those with BRCA mutations. Additionally, also addresses the challenge of resistance mechanisms that can diminish the efficacy of PARP inhibitors over time. Strategies to overcome these resistance mechanisms and enhance the sustained effectiveness of PARP inhibitors in cancer treatment are also discussed.